Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.99% o

MiMedx Group (NASDAQ: MDXG - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free

Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 63,548 shar

Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 54,174 shar

Hsbc Holdings PLC raised its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 1,260.9% d

Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 T

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authori

NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) toda

NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagon

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperfo

Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycy

Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfer

The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offe

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) wit

J&J's portfolio primarily includes small biotech and medtech companies. Its largest investment is in

MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythr

Bamco Inc. NY bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) in the s

NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperfo

Small-cap stocks are surging, but how you own them matters more than most investors realize.

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE f

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-s

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these s

Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral t

Vanguard's tech-heavy portfolio delivered stronger five-year returns despite higher volatility, whil

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $2.29 per share, beating the Zac

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the

ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Prio

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that

Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market

Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the

By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Pat